IVF vs TRIB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a catastrophic 99% decline in share price over the last year. A critical liquidity crisis is evident with a Current Ratio of 0.12 and a Quick Ratio of 0.07, indicating an inability to meet short-term obligations. Negative book value (P/B -0.09) and a massive earnings miss of -158.3% suggest a high risk of insolvency. Despite modest revenue growth, the operational losses and technical collapse make this a high-risk speculative asset.
TRIB exhibits significant financial distress, characterized by a Piotroski F-Score of 4/9 (Stable) which masks deeper systemic issues. The most critical red flag is a negative Price-to-Book ratio (-0.25), indicating negative shareholders' equity. Despite a low Price-to-Sales ratio, the company suffers from negative profit margins (-75.88%) and a catastrophic 5-year price decline of 95.8%. Liquidity is precarious with a Quick Ratio of 0.47, suggesting an inability to meet short-term obligations without inventory liquidation.
Compare Another Pair
Related Comparisons
IVF vs TRIB: Head-to-Head Comparison
This page compares INVO Fertility, Inc. (IVF) and Trinity Biotech plc (TRIB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.